1. Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant.
- Author
-
Jagessar SA, Heijmans N, Blezer EL, Bauer J, Weissert R, and 't Hart BA
- Subjects
- Animals, Antibodies blood, Brain metabolism, Brain pathology, Cell Proliferation drug effects, Cytokines blood, Cytokines genetics, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental etiology, Encephalomyelitis, Autoimmune, Experimental pathology, Female, Freund's Adjuvant adverse effects, Humans, Immunization adverse effects, Leukocytes, Mononuclear metabolism, Leukocytes, Mononuclear pathology, Lipids adverse effects, Lymphocyte Activation immunology, Myelin Sheath metabolism, Myelin Sheath pathology, Myelin-Oligodendrocyte Glycoprotein adverse effects, Peptides adverse effects, Peptides immunology, Recombinant Proteins adverse effects, Recombinant Proteins immunology, Spinal Cord metabolism, Spinal Cord pathology, T-Lymphocytes immunology, Callithrix, Encephalomyelitis, Autoimmune, Experimental immunology, Freund's Adjuvant immunology, Lipids immunology, Myelin-Oligodendrocyte Glycoprotein immunology
- Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset monkey (Callithrix jacchus) is a relevant preclinical model for translational research into immunopathogenic mechanisms operating in multiple sclerosis (MS). Prior studies showed a core pathogenic role of T and B cells specific for myelin oligodendrocyte glycoprotein (MOG). However, in those studies, the quality of the response against MOG epitopes was strongly biased by bacterial antigens in the complete Freund's adjuvant (CFA), in which the immunizing recombinant human (rh) MOG protein had been formulated. In response to the need of a more refined EAE model, we have tested whether disease could also be induced with rhMOG in incomplete Freund's adjuvant (IFA)., Method: Marmosets were immunized with rhMOG emulsified in IFA in the dorsal skin. Monkeys that did not develop neurological deficit were given booster immunizations at 28-day interval with the same antigen preparation. In a second experiment, three marmoset twin pairs were sensitized against MOG peptides in IFA to study a possibility for suppressive activity towards pathogenic T cells directed against the encephalitogenic epitope MOG40-48., Results: Despite the absence of strong danger signals in the rhMOG/IFA inoculum, all monkeys developed clinically evident EAE symptoms. Moreover, in all monkeys, demyelinated lesions were present in the white matter and in two cases also in the cortical grey matter. Immune profiling at height of the disease showed a dominant T cell response against the overlapping peptides 14-36 and 24-46, but reactivity against the pathogenically most relevant peptide 34-56 was conspicuously absent. In the second experiment, there was an indication for a possible suppressive mechanism., Conclusions: Immunization of marmoset monkeys with rhMOG in IFA elicits clinical EAE in all animals. Moreover, rhMOG contains pathogenic and regulatory epitopes, but the pathogenic hierarchy of rhMOG epitopes is strongly influenced by the adjuvant in which the protein is formulated.
- Published
- 2015
- Full Text
- View/download PDF